Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
01:00pm, Thursday, 25'th Apr 2024
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics comp
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
12:50pm, Thursday, 25'th Apr 2024
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance.
Why Bristol Myers Squibb Stock Is Sinking Today
11:57am, Thursday, 25'th Apr 2024
Bristol Myers Squibb beat Wall Street estimates in the first quarter. However, the company slashed its full-year earnings outlook because of recent acquisitions and collaborations.
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
11:50am, Thursday, 25'th Apr 2024
Bristol-Myers Squibb (NYSE: BMY ) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce. Bristol-Myers Squibb has revealed that it w
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:37am, Thursday, 25'th Apr 2024
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics comp
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
09:51am, Thursday, 25'th Apr 2024
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first qu
Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts
08:36am, Thursday, 25'th Apr 2024
The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
07:35am, Thursday, 25'th Apr 2024
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates
07:03am, Thursday, 25'th Apr 2024
Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.911
Bristol Myers posts quarterly loss, revenue rises 5%
07:02am, Thursday, 25'th Apr 2024
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
01:06pm, Wednesday, 24'th Apr 2024
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
10:21am, Wednesday, 24'th Apr 2024
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
03:01pm, Monday, 22'nd Apr 2024
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Is Bristol Myers Squibb A Buy At These Bottom Levels?
09:30am, Monday, 22'nd Apr 2024
BMY has been upgraded to a Buy, with the stock already yielding 5.02% at the time of writing and the Seeking Alpha Quant still grading its dividend safety at B-. Combined with the promising profitabil
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies
07:23am, Monday, 22'nd Apr 2024
Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.
